You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中国生物制药(01177.HK)年度纯利微增0.3%至27.71亿元 末期息2港仙
格隆汇 03-23 16:51

格隆汇3月23日丨中国生物制药(01177.HK)公布,截至2020年12月31日止年度,公司收入约人民币236.47亿元,较去年轻微下降约2.4%;归属于母公司持有者应占盈利约人民币27.71亿元,较去年轻微增长约0.3%;每股基本盈利约人民币14.74分,末期股息每股2港仙。

期间新产品销售占集团总收入约38.1%,达到约人民币90.1亿元,较去年上升约79.3%。抗肿瘤用药销售额约人民币76.2亿元,较去年上升约40.3%。

一直以来,集团十分重视研发,以结合自主创新、联合开发及创仿开发的研发理念,不断提升研发水平和速度,并视其为可持续发展的基础,加大研发的资金投入。该年度,研发总开支约人民币28.5亿元,占集团收入约12.1%,已计入损益表及资本化于财务状况表中。

集团继续专注肝病、抗肿瘤、呼吸系统和心脑血管等治疗领域的新产品研发。于第四季度内,集团获得临床批件5件、生产批件12件及一致性评价获批23个、申报临床6件、一致性评价申报2个及申报生产4个。已累计有临床批件、正在进行临床试验和申报生产的在研产品共391件,其中肝病用药39件、抗肿瘤用药183件、呼吸系统用药22件、内分泌用药20件、心脑血管用药16件及其它类用药111件。集团已累计获得发明专利授权924项、授权实用新型专利31项,以及授权外观设计专利115项。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account